287 related articles for article (PubMed ID: 28669349)
1. Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.
Singla H; Munshi A; Banipal RPS; Kumar V
Curr Cancer Drug Targets; 2018; 18(4):306-327. PubMed ID: 28669349
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for HER2-positive early-stage breast cancer.
Mathew A; Romond EH
Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
5. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Rinnerthaler G; Gampenrieder SP; Greil R
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841523
[TBL] [Abstract][Full Text] [Related]
6. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
Singla H; Ludhiadch A; Kaur RP; Chander H; Kumar V; Munshi A
Eur J Med Chem; 2017 Dec; 142():316-327. PubMed ID: 28800870
[TBL] [Abstract][Full Text] [Related]
8. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
11. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
12. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
13. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Awada A; Bozovic-Spasojevic I; Chow L
Cancer Treat Rev; 2012 Aug; 38(5):494-504. PubMed ID: 22305205
[TBL] [Abstract][Full Text] [Related]
14. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
Garrett JT; Arteaga CL
Cancer Biol Ther; 2011 May; 11(9):793-800. PubMed ID: 21307659
[TBL] [Abstract][Full Text] [Related]
15. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
16. New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab.
Akbari V; Chou CP; Abedi D
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188448. PubMed ID: 33039514
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Duchnowska R; Loibl S; Jassem J
Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
19. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
20. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Singla H; Munshi A
Crit Rev Oncog; 2020; 25(3):241-250. PubMed ID: 33463944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
